Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 1223-1228

  Taipale, Heidi ^a   Koponen, Marjaana ^a   Tanskanen, Antti ^b,c   Tolppanen, Anna Maija ^a   Tiihonen, Jari ^a,b   Hartikainen, Sirpa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Alzheimer's disease; antipsychotic polypharmacy; antipsychotics; prescription register

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

AGE; AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC POLYPHARMACY; ARTICLE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; VERY ELDERLY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEMOGRAPHY; FACTUAL DATABASE; FINLAND; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; RESIDENCE CHARACTERISTICS;

EID: 84923699623     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140282     Document Type: Article

References (26)

1. APA,Work Group on Alzheimer's Disease, other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, Cook IA, FinnertyMT, Johnson BR, Nininger JE, Schneidman B, Summergrad P, Woods SM, Berger J, Cross CD, Brandt HA, Margolis PM, Shemo JP, Blinder BJ, Duncan DL, Barnovitz MA, Carino AJ, Freyberg ZZ, Gray SH, Tonnu T, Kunkle R, Albert AB, Craig TJ, Regier DA, Fochtmann LJ (2007) American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatr 164(12 Suppl), 5-56.
2. Working group set up by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association, the Finnish Association for General Practice (2010) Memory disorders. Current care guideline, http://www.kaypahoito.fi, Accessed July 1, 2013.
3. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice, Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl), 1-56.
4. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aguino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36, 71-93.
5. Lochmann van Bennekom MW, Gijsman H, Zitman FG (2013) Antipsychotic polypharmacy in psychotic disorders: A critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 27, 327-336.
6. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia. Benefits and risks. CNS Drugs 25, 383-399.
7. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitc JH (2005) Atypical antipsychotics and parkinsonism. Arch Intern Med 165, 1882-1888.
8. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S (2009) Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms. J Clin Psychiatry 70, 397-405.
9. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer D, Stroup S, Dagerman KS, Hsaio J, Lebowitz B, Lyketsos C, Tariot PN, Zheng L, Schneider LS (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatr 168, 831-839.
10. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck R (2007) Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multistate Medicaid population, 1998-2003. Clin Ther 29, 183-195.
11. Bernardo M, Coma A, Ibáñez C, Zara C, Bari JM, Serrano-Blanco A (2012) Antipsychotic polypharmacy in a regional health service: A population-based study. BMC Psychiatry 12, 42.
12. Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J (2013) Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol 48, 631-638.
13. Xiang YT, Dickerson F, Kreyenbuhl J, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N (2012) Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009). J Clin Psychopharmacol 32, 809-813.
14. Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR, Shea DG, Stuart B (2005) The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 165, 1280-1285.
15. Martinez C, Jones RW, Rietbrock S (2013) Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: A cohort study. BMJ Open 3, pii: e002080.
16. Tolppanen AM, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, Hartikainen S (2013) Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin Epidemiol 5 277-285.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944.
18. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC.
19. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System. http://www.whocc.no/atc-ddd-index/. AccessedMay22, 2013.
20. Tiihonen J, Lönnqvist J,Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 374, 620-627.
21. Purhonen M, Koponen H, Tiihonen J, Tanskanen A (2012) Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf 21, 1227-1231.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40, 373-383.
23. Kogut SJ, Yam F, Dufresne R (2005) Prescribing of antipsychotic medication in a Medicaid population: Use of polytherapy and off-label dosages. J Manag Care Pharm 11, 17-24.
24. Rochon PA, Gruneir A, Gill SS, Wu W, Fischer HD, Bronskill SE, Normand SL, Austin PC, Seitz DP, Bell CM, Fu L, Lipscombe L, Anderson GM, Gurwitz JH (2013) Older men with dementia are at greater risk thanwomen of serious events after initiating antipsychotic therapy. J Am Geriatr Soc 61, 55-61.
25. Hartikainen S, Klaukka T (2004) Use of psychotropics is high among very old people. Eur J Clin Pharmacol 59, 849-850.
26. Ott BR, Lapane KL, Gambassi G, for the SAGE Study Group (2000) Gender differences in the treatment of behavior problems in Alzheimer's disease. Neurology 54, 427-432.